Trials / Completed
CompletedNCT03036514
Sublingual Sufentanil Tablet System (SSTS) Versus Intravenous Patient Controlled Analgesia After Back Surgery.
Sublingual Sufentanil Tablet System (SSTS) Versus Intravenous Patient Controlled Analgesia (PCIA) With Morphine for Postoperative Pain After Back Surgery. A Single Center Case-control Study.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- University Hospital, Antwerp · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
In this study, numeric rating scale (NRS) and side effects are measured after usage of a sublingual sufentanil tablet system (SSTS) in comparison to intravenous patient controlled analgesia (PCIA).
Detailed description
Sublingual sufentanil tablet system (SSTS) is compared in pain relief and side effect profile with the routinely used intravenous patient controlled analgesia (PCIA) with morphine in the postoperative phase after back surgery. The common use of PCIA with morphine is associated with a rather slow onset-time and active metabolites, with occurrence of potential harmful side effects as sedation and desaturation. This mono-centric project involving American Society of Anesthesiologists (ASA) classification I-II patients undergoing elective neurosurgery (laminectomy) are recruited. Enrolled patients undergo numeric rating scale (NRS) and side effect questionnaire during the first 72h postoperatively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Sublingual sufentanil tablet system | Usage of a new patient-controlled SSTS in the postoperative phase after laminectomy or spinal fusion. |
| DRUG | Patient-controlled intravenous analgesia | Usage of classically used patient-controlled intravenous mophine-based postoperative analgesia after laminectomy or spinal fusion. |
Timeline
- Start date
- 2017-04-05
- Primary completion
- 2019-08-01
- Completion
- 2019-09-01
- First posted
- 2017-01-30
- Last updated
- 2020-03-09
Locations
1 site across 1 country: Belgium
Source: ClinicalTrials.gov record NCT03036514. Inclusion in this directory is not an endorsement.